Last reviewed · How we verify
NCT06355440
Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China
NA trial testing Financial Navigation in Breast Neoplasm Female in 26 participants. Completed in 7 May 2024.
28 March 2024
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 26 |
| Start date | 18 February 2024 |
| Primary completion | 28 March 2024 |
| Estimated completion | 7 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Financial Navigation
- Usual Care
Conditions studied
- Breast Neoplasm Female — all drugs for Breast Neoplasm Female →
- Financial Toxicity — all drugs for Financial Toxicity →
- Financial Navigation — all drugs for Financial Navigation →
Sponsor
Fudan University
Who can join
18 and older, female only, with Breast Neoplasm Female or Financial Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this pilot study is to access the feasibility and impact of a financial navigation program on improving financial toxicity among patients with breast cancer in China. The main questions it aims to answer are: * Is the intervention feasible and acceptable among participants? * Does the intervention enhance participants' cost-related health literacy? * Does the intervention reduce participants' financial toxicity? Researchers will compare the financial navigation program with usual oncology care to preliminarily evaluate its effectiveness. Participants will receive comprehensive information support, including: * Strategies on patient-physician costs discussion * Skills for inquiring and tracking treatment-related costs * Basic knowledge about health insurance * Guidance on accessing and applying for financial assistance * Suggestions for returning to normal life and work * Strategies for holding a financial-related family meeting
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The development and preliminary evaluation of a financial navigation program among patients with breast cancer in China.
Yuan X, Chen L, Sun Y, Kuang Y, et al · · 2025 · cited 3× · PMID 40124659 · DOI 10.1016/j.apjon.2025.100668
Verify or expand the search:
- PubMed search for NCT06355440
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Financial Navigation
Trials testing the same drug.
- NCT06896695 — A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patie · NA · recruiting
- NCT06484140 — Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China · NA · completed
- NCT06295367 — Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) · NA · recruiting
- NCT04931251 — Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings · NA · completed
Other recruiting trials for Breast Neoplasm Female
Currently open trials in the same condition.
- NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
- NCT06711523 — Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy · Phase 3 · active not recruiting
- NCT05277935 — Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib · NA · recruiting
- NCT06234137 — A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrot · NA · recruiting
- NCT04812652 — Digitally Distributed Yoga for Women Treated for Breast Cancer · NA · active not recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06355440 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 25 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06355440.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing